E Fund Management Co. Ltd. Has $79,000 Stock Position in Annexon, Inc. (NASDAQ:ANNX)

E Fund Management Co. Ltd. grew its stake in shares of Annexon, Inc. (NASDAQ:ANNX) by 36.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 15,447 shares of the company’s stock after purchasing an additional 4,086 shares during the period. E Fund Management Co. Ltd.’s holdings in Annexon were worth $79,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in ANNX. Creative Planning increased its position in shares of Annexon by 29.5% during the third quarter. Creative Planning now owns 34,779 shares of the company’s stock valued at $206,000 after purchasing an additional 7,914 shares during the period. GSA Capital Partners LLP increased its holdings in Annexon by 10.7% in the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock valued at $205,000 after buying an additional 3,355 shares during the period. Mutual of America Capital Management LLC increased its holdings in Annexon by 3.1% in the 3rd quarter. Mutual of America Capital Management LLC now owns 659,254 shares of the company’s stock valued at $3,903,000 after buying an additional 19,681 shares during the period. Intech Investment Management LLC acquired a new position in shares of Annexon in the 3rd quarter valued at $154,000. Finally, Massachusetts Financial Services Co. MA raised its position in Annexon by 9.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,160,886 shares of the company’s stock worth $6,872,000 after purchasing an additional 96,085 shares in the last quarter.

Annexon Price Performance

NASDAQ ANNX opened at $2.76 on Monday. The stock’s 50 day simple moving average is $3.75 and its 200 day simple moving average is $5.33. Annexon, Inc. has a one year low of $2.30 and a one year high of $8.40. The firm has a market cap of $294.20 million, a PE ratio of -2.63 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last announced its earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). As a group, equities analysts expect that Annexon, Inc. will post -0.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ANNX has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $16.00 price objective on shares of Annexon in a report on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Annexon in a research note on Tuesday, December 17th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.